Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian stock markets remain buoyant
Wed, 18 Apr 01:30 pm

After a strong opening, Indian stock markets continued to pare initial gains in the last two trading hours. But the indices remained well above the dotted line. Barring FMCG, all the sectoral indices are trading positive. Auto, consumer durables and metal stocks are the biggest gainers.

The BSE-Sensex is trading up 85 points and NSE-Nifty is trading up 28 points. Both BSE Mid Cap index and BSE Small Cap indices are up by 0.8% each. The rupee is trading at 51.6 to the US dollar.

Most of the FMCG stocks are trading strong with Marico and Godrej Consumer being the biggest gainers. As per a leading financial daily, Rohit Surfactants, which sells the popular mass-detergent Ghari, is planning to enter the higher margin mid-detergent segment. The company will launch its new brand, Uni Wash, in the next 2-3 months, reportedly at the same price level as Hindustan Unilever's Rin and Procter & Gamble's Tide, both being aggressive competitors in this category. Rohit Surfactants has been on a growth spree, adding 15 manufacturing units in the past six years and expanding reach to 10 new states over the last three years. The company feels that it has a solid platform which can be leveraged for the new brand to push it. The detergent industry, which is already battling with raw material inflation, is likely to see competition rising with the entry of a new brand. Hindustan Unilever stock is down 0.13%.

Majority of the Indian pharma stocks are trading positive with Glenmark Pharma and Natco Pharma trading the strongest. As per a leading financial daily, the US Supreme Court has given a favourable ruling to Sun Pharmaceuticals' subsidiary Caraco Pharmaceuticals in its patent litigation case against Novo Nordisk. The ruling will enable Caraco to launch generic version of diabetes drug, Prandin, in the US market. The company is likely to launch the drug by FY13. Sun Pharma stock is up 1.7%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian stock markets remain buoyant". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.